Physician profile
Sunil K Dama
NPI 1801845334
$7,175.38
in general payments reported to CMS, 2019-2025
28 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 82% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $658 · 2021: $1,051 · 2022: $1,015 · 2023: $861 · 2024: $1,147 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Travel and Lodging: $913 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.39 |
| Travel and Lodging | $912.95 |
| Education | $221.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $2,087.84 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $1,791.54 | 2020-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,078.82 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $607.84 | 2019-2025 | |
| Grifols USA, LLC | $266.25 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $251.29 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $168.58 | 2019-2020 | |
| Axsome Therapeutics, INC. | $96.19 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $90.76 | 2019-2022 | |
| Pulmonx Corporation | $76.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $71.00 | 2022 | |
| Resmed Corp | $64.52 | 2023-2025 | |
| Astellas Pharma US INC | $56.94 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $51.37 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46.96 | 2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $39.79 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $35.08 | 2023 | Quviviq |
| Philips North America LLC | $32.66 | 2019-2022 | |
| Zoll Respicardia, INC. | $31.17 | 2025 | Remede System |
| Mayne Pharma Commercial LLC | $30.51 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.95 | 2019-2020 | |
| Mylan Specialty L.P. | $22.55 | 2019 | |
| Genzyme Corporation | $18.66 | 2019 | |
| Advanced Respiratory, INC | $16.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.96 | 2021 | |
| Electromed, INC. | $12.01 | 2022 | |
| Amgen INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Dama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.